Doris Benbrook to Recombinant Fusion Proteins
This is a "connection" page, showing publications Doris Benbrook has written about Recombinant Fusion Proteins.
Connection Strength
0.219
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.141
-
Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 2009; 84(5):271-5.
Score: 0.078